Working to Eradicate Gynecologic Cancers

Scientific Plenary VII: Ovarian Cancer Clinical Trials: Endpoint Validation and Practice-Changing Results

Tuesday, March 25, 2014: 7:30 AM-9:00 AM
Ballroom B/C (Tampa Convention Center)
Description:
Moderator:  Robert Allen Burger, MD, University of Pennsylvania, Philadelphia, PA
7:30 AM
Moderator Introductions in Scientific Plenary: Scientific Plenary VII: Ovarian Cancer Clinical Trials: Endpoint Validation and Practice-Changing Results
R. A. Burger
University of Pennsylvania, Philadelphia, PA
 

 
7:36 AM
136 - Scientific Plenary
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 m
R. L. Coleman1, M. Sill2, C. Aghajanian3, H. J. Gray4, K. S. Tewari5, S. C. Rubin6, T. J. Rutherford7, J. K. Chan8, H. X. Chen9 and E. M. Swisher4
1The University of Texas MD Anderson Cancer Center, Houston, TX, 2Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, 3Memorial Sloan Kettering Cancer Center, New York, NY, 4University of Washington Medical Center, Seattle, WA, 5University of California at Irvine, Irvine, CA, 6University of Pennsylvania, Philadelphia, PA, 7Yale University School of Medicine, New Haven, CT, 8UCSF Helen Diller Comprehensive Cancer Center, San Francisco, CA, 9National Cancer Institute, Bethesda, MD
 

 
7:47 AM
137 - Scientific Plenary
Final analysis of overall survival in OCEANS, a randomized phase III trial of gemcitabine, carboplatin, and bevacizumab followed by bevacizumab until disease progression in patients with platinum-sensitive recurrent ovarian cancer
C. Aghajanian1, B. A. Goff2, L. R. Nycum3, Y. Wang4, A. Husain4 and S. V. Blank5
1Memorial Sloan Kettering Cancer Center, New York, NY, 2University of Washington Medical Center, Seattle, WA, 3Novant, Forsyth Regional Cancer Center, Winston-Salem, NC, 4Genentech, Inc., South San Francisco, CA, 5New York University School of Medicine, New York, NY
 

 
7:58 AM
138 - Scientific Plenary
Health-related quality-of-life analysis from the TRINOVA-1 study of weekly paclitaxel plus trebananib or placebo in women with recurrent ovarian cancer
F. Raspagliesi1, C. Lhommé2, B. J. Monk3, R. L. Coleman4, T. J. Herzog5, L. Navale6, D. J. Warner6 and K. Fujiwara7
1Fondazione IRCCS Istituto Nazionale Tumori -Milan, Milan, Italy, 2Institut Gustave Roussy, Villejuif, France, 3University of Arizona Cancer Center, Phoenix, AZ, 4The University of Texas MD Anderson Cancer Center, Houston, TX, 5Columbia University College of Physicians and Surgeons, New York, NY, 6Amgen Inc., Thousand Oaks, CA, 7Saitama Medical University International Medical Center, Hidaka-Shi, Japan
 

 
8:13 AM
139 - Scientific Plenary
Health-related quality of life associated with every-3-week paclitaxel vs dose-dense weekly paclitaxel in combination with carboplatin with or without bevacizumab for primary ovarian cancer: Gynecologic Oncology Group study 262
B. J. Monk1, H. Huang2, R. T. Penson3, S. A. Davidson4, M. L. Pearl5, D. M. O'Malley6, D. P. Bender7, M. P. Boente8, L. P. Martin9, J. K. Chan10, J. L. Walker11 and C. K. McCourt12
1University of Arizona Cancer Center, Phoenix, AZ, 2Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, 3Massachusetts General Hospital/Harvard University, Boston, MA, 4University of Colorado Denver, Aurora, CO, 5Stony Brook University Hospital, Stony Brook, NY, 6The Ohio State University, Columbus Cancer Council, Hilliard, OH, 7University of Iowa Hospitals and Clinics, Iowa City, IA, 8Minnesota Oncology Hematology PA, US Oncology, Edina, MN, 9Fox Chase Cancer Center, Philadelphia, PA, 10UCSF Helen Diller Comprehensive Cancer Center, San Francisco, CA, 11The University of Oklahoma, Oklahoma City, OK, 12Women & Infants Hospital, Brown University, Providence, RI
 

 
8:24 AM
1 - Seminal Abstracts
Seminal Abstract: Presentation of seminal clinical data from Gynecologic Oncology Group study 262 presented at the European Society of Gynecologic Oncology
B. J. Monk
University of Arizona Cancer Center, Phoenix, AZ
 

 
8:30 AM
Questions & Panel Discussion
C. Aghajanian1, R. L. Coleman2, B. J. Monk3 and F. Raspagliesi4
1Memorial Sloan Kettering Cancer Center, New York, NY, 2The University of Texas MD Anderson Cancer Center, Houston, TX, 3University of Arizona Cancer Center, Phoenix, AZ, 4Fondazione IRCCS Istituto Nazionale Tumori -Milan, Milan, Italy
 
See more of: Scientific Plenary
<< Previous Course | Next Course >>